查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553681

肝病治疗药物市场规模、份额和趋势分析报告：按药物类别、疾病、地区和细分市场预测，2024-2030年

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Antiviral Drugs, Vaccines), By Disease (Hepatitis, Autoimmune Diseases, Cancer), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

肝病治疗药物市场成长与趋势：

根据 Grand View Research, Inc. Masu 的最新报告，预计到 2030 年，全球肝病治疗市场将达到 286.2 亿美元，2024 年至 2030 年复合年增长率为 5.7%。

主要驱动因素是肝细胞癌等肝臟疾病的增加以及此类疾病患者的巨大未开发需求。此外，世界老龄化人口的增加预计将增加未来的市场需求。

生物技术和製药行业在研发上的巨额支出以及强大的管道可用性预计将成为未来一段时间推动肝病治疗市场成长的主要因素。政府和大公司的疫苗接种计划正在提高人们对这种疾病和预防的认识，从而促进市场成长。

市场分为两部分：产品和区域。新产品不断推出，推动市场成长。主要企业之间的策略联盟和合资企业以及未来国家不断提高的医疗保健意识推动了市场成长。

肝病药物市场报告亮点

  • 在全球肝病治疗药物市场中，抗病毒药物领域占据主导地位，2023年销售量为30.3%。肝炎的高盛行率导致肝病患者数的增加。
  • 在全球肝病和老年人口盛行率上升的推动下，预计标标靶治疗领域在预测期内的复合年增长率将达到 7.2%。
  • 肝炎细分市场在全球肝病治疗药物市场中占据主导地位，到 2023 年收益占有率将达到 36.6%。
  • 非酒精性脂肪肝病 (NAFLD) 预计将在预测期内成长最快，复合年增长率为 6.6%。此细分市场的成长是由肥胖流行率的增加以及随之而来的肝细胞中脂肪的累积所驱动的。
  • 北美肝病治疗药物市场在全球肝病治疗药物市场中占据主导地位，2023年收益占有率为38.4%。
  • 预计亚太地区肝病治疗市场在预测期内将以 7.4% 的复合年增长率成长最快。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章 肝病治疗药物市场的变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 肝病治疗药物市场分析工具
    • 波特的分析
    • PESTEL分析

第四章肝病治疗药物市场：依药物类别估计与趋势分析

  • 细分仪表板
  • 肝病药物市场：2023年及2030年依药物类别变化分析
  • 抗病毒药物
  • 疫苗
  • 化疗
  • 标靶治疗
  • 免疫抑制剂
  • 免疫球蛋白
  • 皮质类固醇
  • 其他产品

第五章肝病治疗药物市场：依疾病分类的估算与趋势分析

  • 细分仪表板
  • 肝病治疗药物市场：2023年及2030年疾病特异性变异分析
  • 肝炎
  • 自体免疫疾病
  • 非酒精性脂肪肝（NAFLD）
  • 癌症
  • 遗传疾病
  • 其他疾病

第六章 肝病治疗药物市场：区域估计与趋势分析

  • 2023年及2030年肝病药物市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • Takeda Pharmaceutical Company Limited
    • Gilead Sciences, Inc.
    • Johnson &Johnson Services, Inc.
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline PLC
简介目录
Product Code: 978-1-68038-540-3

Liver Disease Therapeutics Market Growth & Trends:

The global liver disease therapeutics market is expected to be valued at USD 28.62 billion by 2030, registering a CAGR of 5.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments' and big companies' vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

Liver Disease Therapeutics Market Report Highlights:

  • The antiviral drugs segment dominated the market in the global liver disease therapeutics market with a revenue share of 30.3% in 2023. The high incidence of hepatitis diseases contributes to the rise in liver disease cases.
  • The targeted therapy segment is expected to register the fastest CAGR of 7.2% over the forecast period, driven by the rising incidence of liver diseases and geriatric population globally.
  • The hepatitis segment dominated the global liver disease therapeutics market with a revenue share of 36.6% in 2023.
  • Non-alcoholic fatty liver disease (NAFLD) is expected to register the fastest growth over the forecast period with a CAGR of 6.6%. Segment growth is fueled by the increasing prevalence of obesity and associated fat accumulation in liver cells.
  • North America liver disease therapeutics market dominated the global liver disease therapeutics market with a revenue share of 38.4% in 2023.
  • Asia Pacific liver disease therapeutics market is expected to have the fastest growth in the forecast period with a CAGR of 7.4%.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Diseases Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
    • 3.3.3. Liver Diseases Therapeutics Market Analysis Tools
    • 3.3.4. Porter's Analysis
      • 3.3.4.1. Bargaining power of the suppliers
      • 3.3.4.2. Bargaining power of the buyers
      • 3.3.4.3. Threats of substitution
      • 3.3.4.4. Threats from new entrants
      • 3.3.4.5. Competitive rivalry
    • 3.3.5. PESTEL Analysis
      • 3.3.5.1. Political landscape
      • 3.3.5.2. Economic and Social landscape
      • 3.3.5.3. Technological landscape
      • 3.3.5.4. Environmental landscape
      • 3.3.5.5. Legal landscape

Chapter 4. Liver Disease Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liver Disease Therapeutics Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Antiviral Drugs
    • 4.3.1. Antiviral Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Vaccines
    • 4.4.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Targeted Therapy
    • 4.6.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Immunosuppressants
    • 4.7.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Immunoglobulins
    • 4.8.1. Immunoglobulins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Corticosteroids
    • 4.9.1. Corticosteroids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Other Products
    • 4.10.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Liver Disease Therapeutics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Liver Disease Therapeutics Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Hepatitis
    • 5.3.1. Hepatitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Autoimmune Diseases
    • 5.4.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Non-alcoholic Fatty Liver Disease (NAFLD)
    • 5.5.1. Non-alcoholic Fatty Liver Disease (NAFLD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Genetic Disorders
    • 5.7.1. Genetic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Other Diseases
    • 5.8.1. Other Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Liver Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Liver Disease Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. UAE Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. F. Hoffmann-La Roche Ltd
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/Strategic Initiatives
    • 7.4.2. Takeda Pharmaceutical Company Limited
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/Strategic Initiatives
    • 7.4.3. Gilead Sciences, Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/Strategic Initiatives
    • 7.4.4. Johnson & Johnson Services, Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/Strategic Initiatives
    • 7.4.5. Merck & Co., Inc.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/Strategic Initiatives
    • 7.4.6. Novartis AG
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/Strategic Initiatives
    • 7.4.7. Pfizer Inc.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/Strategic Initiatives
    • 7.4.8. Sanofi
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/Strategic Initiatives
    • 7.4.9. AbbVie Inc.
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/Strategic Initiatives
    • 7.4.10. Bristol-Myers Squibb Company
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/Strategic Initiatives
    • 7.4.11. GlaxoSmithKline PLC
      • 7.4.11.1. Participant's Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Recent Developments/Strategic Initiatives